Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.41 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.41 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.34 |
| ▸ | TP53 | P04637 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10224275 | 0.72 | DRD2 (0.41) | HDAC6HDAC8HDAC2HDAC11ALDH1A1 | |
| SCHEMBL10224226 | 0.71 | HDAC6 (0.62) | HDAC6HDAC1HDAC8HDAC3HDAC4 | |
| SCHEMBL10224267 | 0.70 | HDAC6 (0.43) | HDAC6HDAC1HDAC8HDAC3HDAC4 | |
| SCHEMBL10224334 | 0.69 | SMN1; SMN2 (0.40) | MAPTLMNAHDAC6HDAC1HDAC8 | |
| SCHEMBL720481 | 0.68 | ABCB1 (0.44) | HDAC6HDAC1HDAC8HDAC3HDAC4 | |
| SCHEMBL721249 | 0.68 | GRM5 (0.51) | MAPTLMNAHDAC6HDAC1ALDH1A1 | |
| SCHEMBL10224298 | 0.65 | HDAC3 (0.33) | MAPTLMNAHDAC6HDAC1HDAC8 | |
| SCHEMBL10224220 | 0.63 | DPP4 (0.41) | HDAC6HDAC1 | |
| SCHEMBL10208238 | 0.62 | HDAC6 (0.38) | HDAC6HDAC1HDAC3HDAC2 | |
| SCHEMBL721914 | 0.62 | HSD11B1 (0.46) | LMNAHDAC6HDAC1HDAC3HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9249142-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2016-02-02 | — | — | US | claimed |
| US-9249142-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2016-02-02 | — | — | US | disclosed |
| US-9249142-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2016-02-02 | — | — | US | disclosed |
| US-9249142-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2016-02-02 | — | — | US | disclosed |
| US-20150105418-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. | 2015-04-16 | — | — | US | disclosed |
| US-20150105418-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. | 2015-04-16 | — | — | US | disclosed |
| US-20150105418-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. | 2015-04-16 | — | — | US | disclosed |
| US-8952163-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-02-10 | — | — | US | disclosed |
| US-8952163-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-02-10 | — | — | US | disclosed |
| US-8952163-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-02-10 | — | — | US | disclosed |
| US-20140142108-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARM INC (US) | 2014-05-22 | — | — | US | disclosed |
| US-20140142108-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARM INC (US) | 2014-05-22 | — | — | US | disclosed |
| US-20140142108-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARM INC (US) | 2014-05-22 | — | — | US | disclosed |
| US-8471026-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-8471026-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-8471026-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20120053201-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-03-01 | — | — | US | disclosed |
| US-20120053201-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-03-01 | — | — | US | disclosed |
| US-20120053201-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053201-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC1, HDAC2 | MAPT 2421/4885LMNA 1044/4885HDAC6 1/4885 |
| US-20140142108-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC1, HDAC2 | MAPT 2421/4885LMNA 1044/4885HDAC6 1/4885 |
| US-20150105418-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC1, HDAC2 | MAPT 2421/4885LMNA 1044/4885HDAC6 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.